<a href="https://www.medchemexpress.com/Olcegepant__hydrochloride_.html">Olcegepant (hydrochloride)</a>产品描述:Olcegepant hydrochloride is the first potent and selective non-peptide antagonist of the <b>calcitonin gene-related peptide 1 (CGRP1) receptor</b> with <b>IC<sub>50</sub></b> of 0.03 nM and with a <b>K<sub>i</sub></b> of 14.4 pM for human CGRP. IC50 & Target: IC50: 0.03 nM (CGRP1)<sup>[1]</sup><br/> Ki: 14.4 pM (hCGRP)<sup>[2]</sup> <i><b>In Vitro:</b></i> Olcegepant possesses higher affinity for the human CGRP receptor than the endogenous ligand CGRP and 150-fold higher affinity compared to the peptidic antagonist CGRP8-37. Olcegepant reverses CGRP-mediated vasodilation in human cerebral vessels and inhibits neurogenic vasodilation in a surrogate animal model of migraine pathophysiology<sup>[1]</sup>. Olcegepant (BIBN4096BS) is extremely potent at primate CGRP receptors exhibiting an affinity (K<sub>i</sub>) for human CGRP receptors of 14.4±6.3 (n=4) pM<sup>[2]</sup>. Several lines of evidence suggest that a calcitonin-gene related peptide (CGRP) receptor antagonist may serve as a<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介绍:MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库,总部位于美国新泽西,分别在瑞典和上海设有欧洲区子公司和亚洲区总代理,营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商, 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域,PI3K、MAPK等近千个细分靶点,超过4000个活性小分子化合物现货,以及GPCR、API、离子通道等超过20种不同类型的化合物库,同时提供从毫克到千克的专业定制合成服务。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 对每批产品都进行严格的LCMS和NMR检验,其产品已被全球近万名客户广泛使用并发表大量文章、专利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各领域热门抑制剂、激动剂,不断扩增已有化合物库,以满足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">数千种产品在上海有充足备货,24-48小时内送达客户;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量产品提供免费试用装;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已为全球多个知名企业、院校构建各种定制型化合物库。</span><br><br>产品链接:<a href="http://www.medchemexpress.cn/olcegepant-hydrochloride.html">www.medchemexpress.cn/olcegepant-hydrochloride.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
Olcegepant (hydrochloride)研究进展
发布日期:2017-10-27 浏览次数:0
核心提示:a href=https://www.medchemexpress.com/Olcegepant__hydrochloride_.htmlOlcegepant (hydrochloride)/a产品描述:Olcegepant hy
- 下一篇:暂无
- 上一篇:Beaucage reagent研究进展
行业动态
更多...
- Olcegepant (hydrochlorid 10-27
- Beaucage reagent研究进展 10-27
- Olcegepant研究进展 10-27
- EC330研究进展 10-27
- CEP-40783研究进展 10-27
- Conduritol B epoxide研究 10-27
- CDD3506研究进展 10-27
- CDD3505研究进展 10-27
- ML364研究进展 10-27
- Biotin-VAD-FMK研究进展 10-27